NCT02886832 is a NA clinical trial of Prostate Health formulation in Prostate Health, sponsored by Supplement Formulators, Inc..

Who is sponsoring NCT02886832?

NCT02886832 is sponsored by Supplement Formulators, Inc..

What drugs are being tested in NCT02886832?

Interventions in NCT02886832: Prostate Health formulation.

What condition does NCT02886832 study?

NCT02886832 studies Prostate Health.

Is NCT02886832 still recruiting?

NCT02886832 is currently completed. Last updated 18 April 2018.

Last reviewed 2018-04-18 · How we verify

NCT02886832

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effects of a Prostate Health Formulation

Completed NA Last updated 18 April 2018

What this trial tests

NA trial testing Prostate Health formulation in Prostate Health in 30 participants. Completed in 27 March 2018.

Timeline

21 September 2016

Primary endpoint
27 February 2018

27 March 2018

Quick facts

Lead sponsor	Supplement Formulators, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	30
Start date	21 September 2016
Primary completion	27 February 2018
Estimated completion	27 March 2018
Sites	1 location across United States

Drugs / interventions tested

Prostate Health formulation

Conditions studied

Prostate Health — all drugs for Prostate Health →

Sponsor

Supplement Formulators, Inc.

Who can join

Adults 45 to 75, male only, with Prostate Health. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy of a Prostate Health formulation on scores attained from the I-PSS questionnaire. Safety and tolerability of the formulation will also be assessed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Self-Assessed Benefits of a Prostate Health Formulation on Nocturia in Healthy Males With Mild Lower Urinary Tract Symptoms: An Open Label Study.
Hirsh SP, Pons M, Joyal SV, Swick AG. · · 2020 · cited 1× · PMID 33294303 · DOI 10.1177/2164956120973639

Verify or expand the search:

Other Supplement Formulators, Inc. trials

Trials by the same sponsor.

NCT07371975 — A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms · NA · recruiting
NCT06419231 — Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated · NA · completed
NCT05854017 — Effects of a Theanine for Stress Relief Formulation in Individuals Who Report Occasional Moderate High Levels of Stress. · NA · active not recruiting
NCT05450952 — Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional · NA · terminated
NCT05170113 — Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulatio · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02886832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Supplement Formulators, Inc.
Last refreshed: 18 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02886832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing